Dr. Martens (LON:DOCS) Insider Sells £144,320.40 in Stock

Key Points

• Insider sale: Dr. Martens insider Ije Nwokori sold 209,160 shares at an average of GBX 69, generating proceeds of £144,320.40. Nwokori had made several smaller purchases in recent months.
• Stock performance: Shares rose 0.9% to GBX 68.80, but remained below their 50-day and 200-day moving averages. The stock has traded between GBX 59.15 and GBX 97.05 over the past year.
• Analyst outlook: Berenberg reaffirmed a “buy” rating with a GBX 110 price target, while the broader analyst consensus is “Moderate Buy” with an average target of GBX 105.

Dr. Martens plc (LON:DOCS - Get Free Report) insider Ije Nwokori sold 209,160 shares of the firm's stock in a transaction that occurred on Friday, October 16th. The stock was sold at an average price of GBX 69, for a total transaction of £144,320.40.

Ije Nwokori also recently made the following trade(s):

• On Monday, October 12th, Ije Nwokori purchased 220 shares of Dr. Martens stock. The shares were purchased at an average cost of GBX 68 per share, with a total value of £149.60.
• On Friday, September 11th, Ije Nwokori bought 232 shares of Dr. Martens stock. The shares were acquired at an average cost of GBX 65 per share, with a total value of £150.80.
• On Tuesday, August 11th, Ije Nwokori bought 179 shares of Dr. Martens stock. The shares were acquired at an average cost of GBX 84 per share, with a total value of £150.36.

Dr. Martens Trading Up 0.9%

LON DOCS traded up GBX 0.60 during mid-day trading on Friday, hitting GBX 68.80. The company's stock had a trading volume of 1,484,075 shares, compared to its average volume of 6,314,625. Dr. Martens plc has a 52-week low of GBX 59.15 and a 52-week high of GBX 97.05. The stock's fifty day simple moving average is GBX 73.35 and its two-hundred day simple moving average is GBX 71.05. The company has a debt-to-equity ratio of 108.85, a current ratio of 2.61 and a quick ratio of 1.13. The firm has a market capitalization of £658.53 million, a P/E ratio of 28.67, a price-to-earnings-growth ratio of 6.40 and a beta of 0.26.

Wall Street Analyst Weigh In

Separately, Berenberg Bank reaffirmed a "buy" rating and set a GBX 110 price target on shares of Dr. Martens in a research report on Friday, October 9th. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of GBX 105.

Dr. Martens Company Profile

Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot - named after the date it was produced - rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, "Docs" or "DM's" were later adopted by musicians and subcultural pioneers who took them from the street to the global stage. Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.